The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Tirzepatide (15 mg once weekly), a dual agonist targeting GLP-1 and GIP receptors, produced weight loss of up to 17.8% after 72 weeks, and semaglutide (2.4 mg once weekly) produced weight loss of ...

Retatrutide, tirzepatide, and semaglutide were most effective for weight loss in adults without diabetes, showing significant reductions in body weight and BMI. Retatrutide led the investigative ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Retatrutide conferred the greatest weight reduction among all GLP-1s. A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...